139 related articles for article (PubMed ID: 21297372)
21. [From pharmacogenetics to pharmacogenomics: the start of a new era of personalized medicine in nephrology].
Zaza G; Granata S; Mangino M; Grandaliano G; Schena FP
G Ital Nefrol; 2010; 27(4):353-66. PubMed ID: 20672232
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenomics of inhaled corticosteroids and leukotriene modifiers: a systematic review.
Farzan N; Vijverberg SJ; Arets HG; Raaijmakers JA; Maitland-van der Zee AH
Clin Exp Allergy; 2017 Feb; 47(2):271-293. PubMed ID: 27790783
[TBL] [Abstract][Full Text] [Related]
23. Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine.
Ji Y; Si Y; McMillin GA; Lyon E
Expert Rev Mol Diagn; 2018 May; 18(5):411-421. PubMed ID: 29634383
[TBL] [Abstract][Full Text] [Related]
24. Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity.
Chan SL; Jin S; Loh M; Brunham LR
Pharmacogenomics; 2015; 16(10):1161-78. PubMed ID: 25978008
[TBL] [Abstract][Full Text] [Related]
25. Alcohol Dependence Genetics: Lessons Learned From Genome-Wide Association Studies (GWAS) and Post-GWAS Analyses.
Hart AB; Kranzler HR
Alcohol Clin Exp Res; 2015 Aug; 39(8):1312-27. PubMed ID: 26110981
[TBL] [Abstract][Full Text] [Related]
26. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients.
Zaza G; Granata S; Sallustio F; Grandaliano G; Schena FP
Clin Exp Immunol; 2010 Mar; 159(3):268-80. PubMed ID: 19968662
[TBL] [Abstract][Full Text] [Related]
28. Use of Pharmacogenomics and Biomarkers in the Development of New Drugs for Alzheimer Disease in Japan.
Otsubo Y
Clin Ther; 2015 Aug; 37(8):1627-31. PubMed ID: 25963998
[TBL] [Abstract][Full Text] [Related]
29. Cancer based pharmacogenomics network supported with scientific evidences: from the view of drug repurposing.
Wang L; Liu H; Chute CG; Zhu Q
BioData Min; 2015; 8():9. PubMed ID: 25729430
[TBL] [Abstract][Full Text] [Related]
30. Polygenic modelling and machine learning approaches in pharmacogenomics: Importance in downstream analysis of genome-wide association study data.
Koido M
Br J Clin Pharmacol; 2023 Sep; ():. PubMed ID: 37743713
[TBL] [Abstract][Full Text] [Related]
31. Functional genomics of candidate genes derived from genome-wide association studies for five common neurological diseases.
Guio-Vega GP; Forero DA
Int J Neurosci; 2017 Feb; 127(2):118-123. PubMed ID: 26829381
[TBL] [Abstract][Full Text] [Related]
32. [Update on the genetics of stroke].
López Fernández JC; Rodríguez Esparragón F; Buset Ríos N
Med Clin (Barc); 2014 Aug; 143(4):176-9. PubMed ID: 24703417
[TBL] [Abstract][Full Text] [Related]
33. The era of genomics: impact on sepsis clinical trial design.
Cariou A; Chiche JD; Charpentier J; Dhainaut JF; Mira JP
Crit Care Med; 2002 May; 30(5 Suppl):S341-8. PubMed ID: 12004257
[TBL] [Abstract][Full Text] [Related]
34. Collaborative Counseling Considerations for Pharmacogenomic Tests.
Zierhut HA; Campbell CA; Mitchell AG; Lemke AA; Mills R; Bishop JR
Pharmacotherapy; 2017 Sep; 37(9):990-999. PubMed ID: 28672074
[TBL] [Abstract][Full Text] [Related]
35. Construction of high-quality recombination maps with low-coverage genomic sequencing for joint linkage analysis in maize.
Li C; Li Y; Bradbury PJ; Wu X; Shi Y; Song Y; Zhang D; Rodgers-Melnick E; Buckler ES; Zhang Z; Li Y; Wang T
BMC Biol; 2015 Sep; 13():78. PubMed ID: 26390990
[TBL] [Abstract][Full Text] [Related]
36. Leveraging lung tissue transcriptome to uncover candidate causal genes in COPD genetic associations.
Lamontagne M; Bérubé JC; Obeidat M; Cho MH; Hobbs BD; Sakornsakolpat P; de Jong K; Boezen HM; ; Nickle D; Hao K; Timens W; van den Berge M; Joubert P; Laviolette M; Sin DD; Paré PD; Bossé Y
Hum Mol Genet; 2018 May; 27(10):1819-1829. PubMed ID: 29547942
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenomics: "noninferiority" is sufficient for initial implementation.
Altman RB
Clin Pharmacol Ther; 2011 Mar; 89(3):348-50. PubMed ID: 21326263
[TBL] [Abstract][Full Text] [Related]
38. Genome-wide association studies of family data in pharmacogenetics: a case study.
Murphy A; Lasky-Su J; Tantisira KG; Litonjua AA; Lange C; Weiss ST
Curr Pharm Des; 2009; 15(32):3764-72. PubMed ID: 19925427
[TBL] [Abstract][Full Text] [Related]
39. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
40. Genomic consequences of selection and genome-wide association mapping in soybean.
Wen Z; Boyse JF; Song Q; Cregan PB; Wang D
BMC Genomics; 2015 Sep; 16(1):671. PubMed ID: 26334313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
